Info
13F
Schedule 13D
Ownership

Slate Path Capital LP - Significant Ownership

Signature - Title: /s/ John Metzner - By: Jades GP, LLC, General Partner, By: John Metzner, Chief Operating Officer
Location: New York, NY
Summary: This page shows a list of all the recent SCHEDULE 13D/G filings made by Slate Path Capital LP.

Significant Ownership of Slate Path Capital LP

Sym	Company	Class	Ownership	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
CUE	Cue Biopharma, Inc.	Common stock, par value $0.001 per share	1.4%	$790K		919K		Slate Path Capital LP	Dec 31, 2024
CYCN	Cyclerion Therapeutics, Inc.	Common Stock, no par value	0%	$0		0		Slate Path Capital LP	Nov 30, 2024

Showing 1 to 2 of 2 entries

Schedules 13D/G Reported by Slate Path Capital LP:

Sym	Target	Class	Ownership	Change	Current Shares	Change	Value	Reporting name	Form	Report Period	Date Filed
CUE	Cue Biopharma, Inc.	Common stock, par value $0.001 per share	1.4%		919K		$790K	Slate Path Capital LP	13G/A	12/31/2024	2/14/2025
CYCN	Cyclerion Therapeutics, Inc.	Common Stock, no par value			0		$0	Slate Path Capital LP	13G/A	11/30/2024	12/6/2024

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.